Italia markets close in 1 hour 20 minutes

FTSE MIB
33.528,52
-178,69(-0,53%)
Dow Jones
38.956,53
-155,63(-0,40%)
Nasdaq
17.767,64
+49,98(+0,28%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
80,98
+0,15(+0,19%)
Bitcoin EUR
57.898,10
+539,18(+0,94%)

NBIX Mar 2025 140.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

17,21

0,00

(0,00%)

In data: 10:31AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat